Luis Valverde

Luis Valverde is an accomplished professional in the biopharmaceutical industry, currently serving as VP and Commercialization Lead for empasiprubart/ARGX-119 at argenx since December 2023. Previously, Valverde held multiple senior roles at Biogen, including Executive Director for Neuromuscular Diseases in the Intercontinental Region and Director of Business Excellence for the European region. Valverde's career also includes significant positions at Cerus, BMEYE B.V., Genzyme Europe, Organon Biosciences/Schering-Plough, and Mexichem. Valverde's educational background features an MBA from Nyenrode Business University, alongside advanced studies in management of biotech and pharma ventures from EPFL and a certificate program from Harvard Medical School focusing on genetic testing and sequencing technologies.